New Combination Therapy Shows Superiority for EGFR-Mutated Lung Cancer

The Phase III SAFFRON study found that combining osimertinib and savolitinib is more effective than chemotherapy for patients with EGFR-mutated non-small cell lung cancer who developed MET alterations after prior EGFR inhibitor treatment. This finding, highlighted by PHARMASTAR, suggests a new, improved therapeutic strategy for this challenging patient population, potentially extending progression-free survival.